TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03441204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LTOT 24 h/day
Description: LTOT prescribed for 24 h/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LTOT 15h/day
Description: : LTOT prescribed for 15 h/day. The patient is instructed to use LTOT during sleep and not to use LTOT for about 9 hours during daytime, totalling 15 h/day.
Study: NCT02880241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048
Description: Tablets of 20mg each

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048
Description: Tablets of 20mg each

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048
Description: Tablets of 20mg each

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048
Description: Tablets of 20mg each

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048
Description: Tablets of 20mg each

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048
Description: Tablets of 20mg each
Study: NCT00084903

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colposcopic biopsy
Description: Two small samples of cervical tissue (biopsy) removed from 2 sites as spectroscopy readings.
Study: NCT00557193

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asparaginase
Description: Given IV, IM, or PO
Study: NCT00084903

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Light-Scattering Spectroscopy
Description: Spectroscopy readings taken in 2 regions of cervix.
Study: NCT01901510

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chromoendoscopy (Indigo Carmine)
Description: Indigo Carmine will be added to the colonic prep to attempt indirect chromoendoscopy

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: The control will have minimal Indigo Carmine added to the colonic prep. This will serve to color the solution blue for blinding but not enough to provide significant staining for chromoendoscopy.
Study: NCT00557193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase
Description: Given IV, IM, or PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT04054635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride
Description: Antibiotic liquid with anti-caries effects. A non-restorative option to manage cavitated caries lesions. Approved for clinical use in Canada in 2017.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride
Description: Antibiotic liquid with anti-caries effects. A non-restorative option to manage cavitated caries lesions. Approved for clinical use in Canada in 2017.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride
Description: Antibiotic liquid with anti-caries effects. A non-restorative option to manage cavitated caries lesions. Approved for clinical use in Canada in 2017.
Study: NCT04584099

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency device treatment
Description: TempSure firm
Study: NCT01911169

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 5,000 International units versus 400 international units as an active comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: 5,000 International units versus 400 international units as an active comparator
Study: NCT03420209

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group applying PNF technique
Study: NCT03189316

Intervention type: OTHER
Group type: OTHER
Intervention: peritoneal fluid and blood sample
Description: Peritoneal fluid sample obtained from peritoneal dialysis fluid of patients with chronic renal insufficiency and blood sample or Peritoneal fluid obtained from coelioscopy for exploration of ovarian cysts and blood cell

Intervention type: OTHER
Group type: OTHER
Intervention: peritoneal fluid and blood sample
Description: Peritoneal fluid sample obtained from peritoneal dialysis fluid of patients with chronic renal insufficiency and blood sample or Peritoneal fluid obtained from coelioscopy for exploration of ovarian cysts and blood cell
Study: NCT02789917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual Therapy
Description: Combination of Apixaban 5mg/dl (or in reduced dosing of 2.5 mg/d depending on age, renal function and body weight) in combination with Clopidogrel 75 mg/d for 6 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Triple Therapy
Description: HAS-BLED-Score \<3:~Combination of Phrenprocoumon (INR 2.0-2.5), Clopidogrel (75mg/d) and ASA (100 mg/d) for 6 months.~HAS-BLED-Score ≥ 3:~Combination of Phrenprocoumon (INR 2.0-2.5), Clopidogrel (75mg/d) and ASA (100 mg/d) for 1 month followed by Phrenprocoumon (INR 2.0-3.0) and Clopidogrel (75mg/d) for 5 months.
Study: NCT03053388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Nitric Oxide given via inhalation in cycles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive treatment
Description: Supportive treatment (including oxygen)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supportive treatment
Description: Supportive treatment (including oxygen)
Study: NCT00891930

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab 6 mg/kg administered via IV infusion over 60 minutes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ganitumab
Description: AMG 479 12 mg/kg adminstered by IV infusion over 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan starting dose of 180 mg/m² adminstered via IV infusion
Study: NCT03098810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc sulphate
Description: Oral syrup zinc sulphate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral syrup placebo
Study: NCT01801878

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Normal saline inject to the half of irradiated breast
Study: NCT00568997

Intervention type: DRUG
Intervention: Pimecrolimus
Description: Pimecrolimus 1% cream
Study: NCT05737173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leukocyte-rich platelet-rich plasma
Description: Intra-articular knee injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leukocyte-rich platelet-rich plasma
Description: Intra-articular knee injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leukocyte-poor platelet-rich plasma
Description: Intra-articular knee injection
Study: NCT02045836

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes Zoster vaccine GSK 1437173A
Description: 2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Herpes Zoster vaccine GSK 1437173A
Description: 2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
Study: NCT05737173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leukocyte-poor platelet-rich plasma
Description: Intra-articular knee injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: Intra-articular knee injection
Study: NCT01988688

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS)
Description: Deep Brain Stimulation (DBS) bilaterally in area LC.
Study: NCT05737173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: Intra-articular knee injection
Study: NCT02410850

Intervention type: DEVICE
Intervention: Oral Appliance
Description: Mandibular Advancement Splints

Intervention type: DEVICE
Intervention: Oral Appliance
Description: Mandibular Advancement Splints

Intervention type: DEVICE
Intervention: Oral Appliance
Description: Mandibular Advancement Splints

Intervention type: DEVICE
Intervention: Oral Appliance
Description: Mandibular Advancement Splints
Study: NCT02138682

Intervention type: DRUG
Intervention: l-123 Ioflupane
Description: 5 millicuries of Ioflupane
Study: NCT02368015

Intervention type: OTHER
Group type: OTHER
Intervention: Peripheral intravenous cannula (IVC)
Description: Blood samples will be withdrawn prior, during and after the procedure using an additional peripheral intravenous cannula (IVC).
Study: NCT02410850

Intervention type: DEVICE
Intervention: Oral Appliance
Description: Mandibular Advancement Splints

Intervention type: DEVICE
Intervention: Oral Appliance
Description: Mandibular Advancement Splints

Intervention type: DEVICE
Intervention: Oral Appliance
Description: Mandibular Advancement Splints

Intervention type: DEVICE
Intervention: Oral Appliance
Description: Mandibular Advancement Splints

Intervention type: DEVICE
Intervention: Oral Appliance
Description: Mandibular Advancement Splints

Intervention type: DEVICE
Intervention: Oral Appliance
Description: Mandibular Advancement Splints

Intervention type: DEVICE
Intervention: Oral Appliance
Description: Mandibular Advancement Splints

Intervention type: DEVICE
Intervention: Oral Appliance
Description: Mandibular Advancement Splints

Intervention type: DEVICE
Intervention: Oral Appliance
Description: Mandibular Advancement Splints
Study: NCT01321931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: 6 mg experimental Nicotine Replacement Therapy (NRT)
Study: NCT02045836

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™
Description: One dose administered intramuscularly (IM) in the deltoid region of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™
Description: One dose administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
Study: NCT02368015

Intervention type: DRUG
Group type: OTHER
Intervention: cefazolin
Study: NCT02487667

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic exercise by fitness machines
Description: Therapeutic exercise program by using 8 exercise machine circuit
Study: NCT01130454

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Universal Electrophysiological Biofeedback Treatment
Description: one 45 minute biofeedback treatment

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Universal Electrophysiological Biofeedback Treatment
Description: one 45 minute placebo treatment
Study: NCT04094883

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Group B Vaccine
Description: All participants will receive the 4CMenB vaccine, 0.5 mL, at entry (Day 0) and at week 5.
Study: NCT04075760

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coils + Cyanoacrylate Group + beta-blocker
Description: EUS-combined coiling and cyanoacrylate injection into the feeder vessel of GOV II and IGV I~Patients with Gastric Varices GOV II or IGV I that have never bleed and are of high-risk GV according to Baveno VI consensus will be prophylactically obliterated via the EUS-guided coiling and cyanoacrylate injection. Patients will also be on beta-blocker therapy as indicated in the other group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: beta blocker therapy
Description: A beta-blocker (propranolol) was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was \> 90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure \< 90 mm Hg or pulse rate \< 55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
Study: NCT01321931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: 6 mg experimental Nicotine Replacement Therapy (NRT)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: 4 mg marketed Nicotine Fruit Gum (NFG)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: 4 mg marketed Nicotine Fruit Gum (NFG)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: 4 mg marketed nicotine mint lozenge (NIQ)
Study: NCT00509496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 25 mg/m\^2/day intravenous piggy back over 30 minutes for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 25 mg/m\^2/day intravenous piggy back over 30 minutes for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 60 mg/kg/day x 2 days intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 60 mg/kg/day x 2 days intravenous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: 720,000 IU/kg intravenously over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
Study: NCT04737382

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: biopsy
Description: The formalin fixed material will be processed for molecular analysis in a clinically validated diagnostic pipeline according to ISO 15189 or other acceptable standard
Study: NCT02341625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986148
Study: NCT00509496

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: 720,000 IU/kg intravenously over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous anti-gp 100:154-162 T-cell receptor gene-engineered tumor infiltrating lymphocytes
Description: Patients will receive a minimum of approximately 5 X 10\^8 cells and up to 3 x10\^11 anti-gp100:154-162 TCR engineered TIL .~The cells are infused intravenously over 20-30 minutes.
Study: NCT02341625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986148

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study: NCT04838158

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Isokinetic measurements
Description: Each patient underwent an isokinetic examination on Biodex System 3 (Biodex Multi-Joint System - Pro, Biodex Medical Systems, Inc. New York, USA). In the study group, both side hamstring muscle were evaluated at the velocities of 60 and180 deg/s for the following parameters: peak torque (PT), torque in 30 degree of the knee flexion (T 30 deg.), angle of peak torque (APT) and peak torque hamstring to quadriceps ratio (H/Q ratio).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Isokinetic measurements
Description: Each patient underwent an isokinetic examination on Biodex System 3 (Biodex Multi-Joint System - Pro, Biodex Medical Systems, Inc. New York, USA). In the study group, both side hamstring muscle were evaluated at the velocities of 60 and180 deg/s for the following parameters: peak torque (PT), torque in 30 degree of the knee flexion (T 30 deg.), angle of peak torque (APT) and peak torque hamstring to quadriceps ratio (H/Q ratio).
Study: NCT01430858

Intervention type: DEVICE
Group type: OTHER
Intervention: Strain Gauge
Description: The study participants will each undergo sterile surgical implantation of a tibial bone strain gauge in the right leg (dominance will recorded and determined by handedness). A single stacked, 45°, rosette strain gauge (FRA-2-11 Tokyo Sokki Kenkyujo Co., Japan) will be unilaterally bonded to the medial tibial cortex and carefully aligned with the long axis of the tibia. The gauge will be attached at the mid-shaft region, to determine the transmission of the vibrations through the bone and quantification of the microstructural effect.
Study: NCT00509496

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes
Description: Patients will receive a minimum of approximately 5 X 10\^8 cells and up to 3 x10\^11 anti-gp100:154-162 TCR engineered PBL.~The cells are infused intravenously over 20-30 minutes.
Study: NCT02643186

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: preoperative vaginal misoprostol
Description: preoperative vaginal misoprostol 400 micrograms 1 hour before surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral uterine artery ligation
Description: bilateral ascending uterine artery ligation at the level of uterine isthmus with 2/0 vicryl sutures
Study: NCT04086069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sit-to-stand trainer
Description: The sit-to-stand trainer device is an exoskeleton that enables standing-up movement resembling the movement of a healthy person. It consists of three sub-systems: a foldable chair, a lever for body orientation and a triggering mechanism. It includes a support for feet with adjustable height. The device offers partial support to the patient while standing up. The patient will exercise with the device for 10 sessions (one per day), standing up for up to 30 times per session.
Study: NCT00914602

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sinemet 25-100 Oral Tablet
Description: After screening all subjects will be placed on a fixed dosing Sinemet® time regimen for approximately 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP21279
Description: Upon completion of Sinemet® treatment eligible subjects will be placed on a fixed dosing time regimen of XP21279 (with Lodosyn®).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa Pill
Study: NCT02834546

Intervention type: BIOLOGICAL
Intervention: Sorafenib plasma concentration 4 weeks after treatment initiation
Description: Sorafenib plasma concentrations will be assessed at 4, 8 and 16 weeks by high performance liquid chromatography. The pharmacology Unit of Bordeaux university hospital (Pr Molimard) is a French Center of reference for the dosage of TKI in the plasma
Study: NCT02121756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Description: Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo, then Dipyridamole
Description: Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24
Study: NCT04476199

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Venetoclax and Decitabine
Description: The prognosis of acute myeloid leukemia (AML) patients aged over 60 years is poor and allogeneic stem cell transplantation (allo-SCT) is the only curative option.The association VEN-DEC is a promising combination therapy for AML elderly patients who are fit and eligible for allo-SCT.
Study: NCT03122717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: gefitinib is a EGFR inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: An orally available, irreversible, third-generation, mutant-selective epidermal growth factor receptor (EGFR) inhibitor
Study: NCT01039194

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: galantamine
Description: Capsule, Oral, 8 mg (ER), once daily, Days 1-7

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: galantamine
Description: Capsule, Oral, 16 mg (ER), once daily, Days 8-24

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-708163
Description: Capsule, Oral, 125 mg, once daily, Days 15-24
Study: NCT00932945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LACTIC ACID(ND)
Description: Treatment duration: 21 consecutive days
Study: NCT01430858

Intervention type: OTHER
Group type: OTHER
Intervention: Vibration therapy
Description: Galileo 900 platform. Study subjects will be asked to stand on the device for a series of 36 tests, with vibrations applied at various frequencies and amplitudes. A 20-second duration of videomotion \& strain gauge readings will be captured.~Juvent 1000 platform The volunteers will stand on the platform for one minute during which a 20-second duration of videomotion \& strain gauge readings will be captured.~Power Plate Pro5 Two amplitude settings will be tested, described as low \& high. The subject will stand on each platform test for up to 1 minute, during which a 20-second duration of videomotion \& strain gauge readings will be captured.
Study: NCT01379014

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid Tool
Description: A booklet which outlines to pros and cons of different decision outcomes, and is designed to assist the user in making a decision according to their own specific circumstances

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Treatment as Usual
Description: The control group does not receive a copy of the decision aid tool booklet, instead received treatment as usual from vocational specialist
Study: NCT02888808

Intervention type: OTHER
Intervention: Gastroscopy
Description: Upper gastrointestinal endoscopy procedure

Intervention type: OTHER
Intervention: Gastroscopy
Description: Upper gastrointestinal endoscopy procedure
Study: NCT02006940

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: miniprobe Alveoflex
Description: Alveoflex uses 488nm laser, generating real time moving images with an optical area of 600μm at a video frame rate of 12 images per second and a focus depth of 50μm